Cellectar Biosciences, Inc.
CLRB
$3.17
-$0.09-2.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 51.12% | 62.38% | 45.11% | 60.56% | -4.23% |
| Total Depreciation and Amortization | -26.74% | -20.57% | -6.25% | 8.85% | 51.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 201.19% | -300.32% | -147.89% | -169.52% | -123.31% |
| Change in Net Operating Assets | -81.19% | -4,718.76% | 10.24% | -1,165.32% | -149.65% |
| Cash from Operations | 51.42% | 35.83% | 23.44% | -13.10% | -46.97% |
| Capital Expenditure | 94.34% | 80.21% | 93.24% | 90.67% | 87.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 94.34% | 80.21% | 93.24% | 90.67% | 87.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -78.78% | -90.43% | -70.34% | -73.71% | 167.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -78.78% | -87.00% | -70.34% | -73.71% | 167.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -173.54% | -242.10% | -171.58% | -195.53% | 233.22% |